(Q37802888)

23 August 2017

Diabetes mellitus and increased risk of cancer: focus on metformin and the insulin analogs (English)

1 reference

23 August 2017

1 reference

M Shawn McFarland

1

1 reference

PubMed ID

20973689

23 August 2017

Rebecca Cripps

series ordinal

2

1 reference

PubMed ID

20973689

23 August 2017

language of work or name

English

0 references

publication date

1 November 2010

1 reference

23 August 2017

1 reference

23 August 2017

30

1 reference

23 August 2017

11

1 reference

23 August 2017

1159-1178

1 reference

The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence

23 August 2017

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.11.1159

Diabetes mellitus and risk of colorectal cancer: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.11.1159

Diabetes mellitus and risk of endometrial cancer: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.11.1159

Diabetes mellitus and risk of bladder cancer: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.11.1159

Diabetes mellitus and risk of breast cancer: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.11.1159

The role of obesity and related metabolic disturbances in cancers of the colon, prostate, and pancreas

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.11.1159

Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.11.1159

The influence of glucose-lowering therapies on cancer risk in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.11.1159

Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.11.1159

Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.11.1159

Metformin and reduced risk of cancer in diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.11.1159

New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.11.1159

Long-term metformin use is associated with decreased risk of breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.11.1159

Cancer risk in patients with diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.11.1159

Cancer incidence in a population-based cohort of patients hospitalized with diabetes mellitus in Denmark.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.11.1159

Risk of pancreatic cancer following diabetes mellitus: a nationwide cohort study in Sweden

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.11.1159

Diabetes mellitus and pancreatic cancer mortality in a prospective cohort of United States adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.11.1159

Prospective study of adult onset diabetes mellitus (type 2) and risk of colorectal cancer in women

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.11.1159

Fasting serum glucose level and cancer risk in Korean men and women

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.11.1159

Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.11.1159

Type 2 diabetes mellitus and risk of non-Hodgkin lymphoma: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.11.1159

Diabetes and risk of Non-Hodgkin's lymphoma: a meta-analysis of observational studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.11.1159

Nutrition, insulin, insulin-like growth factors and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.11.1159

A prospective study of C-peptide, insulin-like growth factor-I, insulin-like growth factor binding protein-1, and the risk of colorectal cancer in women.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.11.1159

Cancer as an endocrine problem

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.11.1159

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.11.1159

Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.11.1159

Metformin disrupts crosstalk between G protein-coupled receptor and insulin receptor signaling systems and inhibits pancreatic cancer growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.11.1159

In vitro metformin anti-neoplastic activity in epithelial ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.11.1159

Antidiabetic therapies affect risk of pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.11.1159

Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.11.1159

Does diabetes therapy influence the risk of cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.11.1159

The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.11.1159

AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.11.1159

Insulin analogs with improved pharmacokinetic profiles

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.11.1159

Insulin aspart (B28 asp-insulin): a fast-acting analog of human insulin: absorption kinetics and action profile compared with regular human insulin in healthy nondiabetic subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.11.1159

Analysis of signaling pathways related to cell proliferation stimulated by insulin analogs in human mammary epithelial cell lines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.11.1159

Evaluation of the carcinogenic potential of insulin glargine (LANTUS) in rats and mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.11.1159

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.11.1159

Associations of hyperglycemia and insulin usage with the risk of cancer in type 2 diabetes: the Hong Kong diabetes registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.11.1159

21 January 2018

Identifiers

DOI

10.1592/PHCO.30.11.1159

1 reference

23 August 2017

1 reference

PubMed ID

20973689